reviewTop 1% cited

Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

The Journal of Urology · 2002 · Vol. 168(5) · pp. 1964–1970

Richard Sylvester✉(European Organisation for Research and Treatment of Cancer)Adrian P.M. van der Meijden(European Organisation for Research and Treatment of Cancer)Donald L. Lamm(European Organisation for Research and Treatment of Cancer)

View via DOI Publisher page

Abstract

Intravesical BCG significantly reduces the risk of progression after transurethral resection in patients with superficial bladder cancer who receive maintenance treatment. Thus, it is the agent of choice for patients with intermediate and high risk papillary tumors and those with carcinoma in situ.

Bladder and Urothelial Cancer Treatments Urinary and Genital Oncology Studies Urological Disorders and TreatmentsMedicineCarcinoma in situRandomized controlled trialBladder cancerOdds ratioStage (stratigraphy)UrologyTumor progressionSurgeryClinical trial

MeSH terms

Administration, IntravesicalBCG VaccineUrinary Bladder NeoplasmsCarcinoma in SituCarcinoma, Transitional CellHumansNeoplasm StagingSurvival RateRandomized Controlled Trials as TopicDisease Progression

Citations

1,296

FWCI

26.77

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update